A private, screened luncheon for regional and international investors seeking syndicate partners.
RESI Boston | Wednesday, September 23 | 75 Seats
|
RSVP for Cross-Border Investor Luncheon Today |
By Dennis Ford, Founder & CEO, Life Science Nation (LSN)
Nearly nine out of ten life science startups fail. Not because the science is poor, but because they never connect to the right capital and strategic partners. Solving that is the reason Life Science Nation exists, and for more than fifteen years our work has come down to one thing: finding parties who need each other and matching them.
As some readers know, LSN has been addressing this pervasive dilemma through the LSN Labs Anchor Node Program. An Anchor Node combines LSN’s commercialization methodology and global capital formation network with a regional partner’s laboratories, entrepreneurial programs, and operating platform to produce investment-ready life science companies.
As we expanded the Anchor Node Program across Boston, Australia, Japan, Korea, the UK, and Brazil, a clear pattern emerged: regional partners constantly brought their local VCs to the table seeking international capital. At the same time, our own data across five global RESI events revealed that twenty percent of all partnering meetings were already investor-to-investor.
So we decided to formalize it, and provide a dedicated room for these partners to connect.
The Cross-Border Investor Luncheon, CBIL, is a private luncheon at RESI Boston for regional and international investors seeking syndicate partners. Regional investors have access to exceptional companies that often never reach international investors. International investors have access and reach that regional funds cannot build alone. Both are looking for the same thing across Asia, Europe, North America, and South America.
Attendance is screened. CBIL is for active investors seeking syndicate partners outside their own region, whether that means bringing international capital into local deals or gaining access to deal flow in regions where they have no presence.
Taking place on Wednesday, September 23, CBIL follows the format of the Global Family Office BioForum luncheon (GFOB luncheon takes place on Tuesday, September 22), now in its eighth year. Across those eight years, GFOB has brought family offices together to find each other, form alliances, and build syndicates. CBIL is the natural next step, applying the same private, curated format to the international investor community.
“The future of life science investing is not just finding great companies. It is finding great syndicate partners in the global arena.”
Dennis Ford, Founder and CEO, Life Science Nation
Wednesday, September 23 | Private luncheon | Screened RSVP | 75 seats
Every RSVP is reviewed. Request your seat today!
|
RSVP for Cross-Border Investor Luncheon Today |
Prepare for RESI Boston: Join Our Pre Conference Webinar Series
By Karen Deyo, VP of Product, Israel BD, LSN
Success at RESI Boston begins long before the conference starts. In the weeks leading up to the event, Life Science Nation is hosting a series of complimentary educational webinars designed to help innovators strengthen every aspect of their fundraising journey. From refining your messaging and marketing collateral to learning about emerging technologies, preparing your investor pitch, and navigating the RESI partnering system, these sessions will help you arrive at RESI Boston ready to maximize every opportunity.
Whether you are preparing for investor meetings, applying to the Innovator’s Pitch Challenge, or looking to sharpen your fundraising strategy, these webinars provide practical insights you can immediately put into action.
Branding and Messaging from Seed to Series B: Building Marketing Collateral That Attracts Investors
Monday, August 3 | 11:00 AM ET
Your marketing collateral is often the first impression investors have of your company. This interactive workshop explores how to build a compelling and consistent investment story across your tagline, elevator pitch, executive summary, one page tear sheet, and pitch deck.
Attendees will learn how to effectively communicate the three pillars’ investors evaluate: your technology, your market opportunity, and your business strategy while tailoring messaging for different audiences and strengthening materials through investor feedback.
Register: https://go.lifesciencenation.com/osolca
RESI Boston Partnering Tutorial
Tuesday, August 18 | 11:00 AM ET
The RESI partnering system is one of the most valuable tools available to attendees, but maximizing its potential requires the right strategy. Join the Life Science Nation team for a walkthrough of the partnering platform, including how to identify the best fit investors and strategic partners, manage outreach effectively, develop a successful meeting request strategy, follow up with purpose, and leverage RESI content to maximize your conference experience.
Registration: https://go.lifesciencenation.com/q5QmbZ
Educational Webinars Hosted by RESI Boston Sponsors
In addition to Life Science Nation’s educational workshops, RESI Boston sponsors are offering complimentary webinars that showcase their expertise and provide valuable insights for the life science community.
Biocytogen Webinar
RenSuper Workstation: An AI Driven Antibody Discovery Platform From Target to Antibody Leads in Click
Wednesday, August 26 | 1:00 PM ET
Discover how Biocytogen’s AI driven RenSuper Workstation integrates immunization, next generation sequencing, AI powered high throughput screening, and experimental validation to accelerate antibody discovery and deliver development ready antibody candidates.
Register: https://go.lifesciencenation.com/tooA7s
RSM Webinar – Life Sciences Strategic Managed Services Leader
RSM, a global consulting, tax, and assurance firm with deep expertise serving the life sciences industry, will host a complimentary webinar focused on helping emerging companies navigate growth, fundraising, and commercialization.
Tuesday, September 1 | 12:00 PM ET
Join RESI Boston sponsor RSM for a complimentary webinar featuring insights and expertise for life science companies preparing to grow, raise capital, and navigate today’s evolving business landscape.
Register: https://go.lifesciencenation.com/deHMNq
Maximizing the Power of Your Pitch
Thursday, September 17 | 11:00 AM ET
Just days before RESI Boston begins, this workshop will help innovators prepare one of the most important moments of fundraising: the investor pitch.
Learn practical techniques for crafting a compelling presentation, navigating the application process, delivering an engaging pitch, and confidently handling investor led questions and answers. Whether you are participating in the Innovator’s Pitch Challenge or meeting investors one on one, this session will help you present your company with confidence.
Register: https://go.lifesciencenation.com/akrBbw
Together, these webinars provide a comprehensive roadmap for RESI Boston preparation. From developing a compelling investment story and learning from industry experts to mastering the partnering platform and delivering a winning pitch, each session is designed to help you maximize every investor interaction before the conference begins.
Register for the webinars that best fit your fundraising needs and arrive at RESI Boston fully prepared to connect with investors, strategic partners, and industry leaders.
Finding the Right Investors Starts with the Right Data
By Max Braht, VP of Business Development, LSN
For early-stage life science companies, fundraising success depends on connecting with investors who are actively looking for technologies like yours. That is why Life Science Nation (LSN) has spent years building one of the industry’s most comprehensive investor databases, designed specifically to help innovators identify the right capital partners.
Unlike generic databases built through web scraping, the LSN Investor Database is curated directly through 1:1 interviews with investors and strategic in-licensors, providing startups with insights that go far beyond basic contact information or what you find on an investor’s website. Each investor profile includes valuable details such as typical check size, preferred modalities and indications, stage of development, geographic focus, and more, allowing companies to build a highly targeted fundraising strategy.
The database includes more than 4,000 global investment firms across 10 distinct investor categories and over 12,000 investor contacts spanning therapeutics, medical devices, diagnostics, digital health, and other life science sectors. Whether you are raising a Seed, Series A, or Series B round, identifying investors who are an actual fit can save significant time and improve the quality of your outreach.
Not sure where to begin? Life Science Nation is offering a complimentary investor search to help companies uncover potential investors that may not already be on their radar. The search demonstrates how the LSN Investor Database can provide each company with a curated list of investors matched to their technology and stage of development, along with contact information to then go out and execute on a fundraising campaign.
LSN is also happy to offer a free Fundraising Readiness Assessment through our internally developed AI Agent. The assessment will generate a 6-page report that can be used to help transition your companies’ story from an “interesting technology” into a compelling and ultimately investable company.
Book your free investor search today or complete the AI assessment to take the first step toward building a more focused and effective fundraising campaign.
| Book Your Free Investor Search Today |
Hot Investor Mandate: VC Firm Seeks to Invest in Seed and Series A Technology-Enabled Healthcare Solutions With Focus on Europe-Based Companies
The firm is an investment firm based in Europe that is developing a growth-focused investment strategy spanning life sciences and professional services. Founded by entrepreneurs with a successful track record of building and exiting a global technology company, the firm seeks to support innovation and long-term business growth through both early-stage venture investments and investments in established businesses. Within life sciences, the firm typically invests up to approximately €500K in Series A financings, with smaller investments at the Seed stage. The firm generally invests alongside other institutional investors through syndicated rounds.
The firm invests in life science and healthcare companies developing innovative, technology-enabled solutions. Its primary focus is on businesses with scalable, service-oriented or technology-driven business models. While the firm is open to early-stage opportunities, it favors companies that have demonstrated a viable business model and a clear pathway toward commercial scale.
From a company and management team perspective, the firm seeks founders with compelling value propositions that address meaningful unmet needs. The firm typically participates as a co-investor and provides value beyond capital through its entrepreneurial experience, deep industry expertise, and extensive professional network.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Hot Investor Mandate: CVC Arm of Global Healthcare Business Makes Strategic Investments in Early-Stage Companies With Novel Therapeutic Approaches
The firm is the corporate venture capital arm of a global diversified healthcare and life sciences company with operations spanning food, healthcare, and advanced biological sciences. The firm invests strategically to support innovation across several long-term growth areas, with healthcare serving as a key focus. The firm primarily invests in Seed and Series A companies, committing up to approximately $4M in initial equity investments while reserving capital for follow-on financings. The firm invests globally, with a particular focus on opportunities in North America and Europe.
The firm is primarily interested in early-stage biotechnology companies developing novel therapeutic platforms and differentiated treatment modalities. The firm is modality-agnostic and evaluates opportunities across small molecules, biologics, antibody-drug conjugates (ADCs), oligonucleotide therapeutics, cell therapies, and gene therapies. Platform technologies are of particular interest. The firm invests in companies from the preclinical through early clinical stages and is generally indication-agnostic, prioritizing highly innovative science with broad strategic potential.
From a company and management team perspective, the firm does not impose specific requirements regarding leadership composition. The firm places the greatest emphasis on novel science and differentiated technology. The firm generally prefers to participate as a co-investor and does not typically seek board representation.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Hot Investor Mandate: Western Europe VC Invests in Therapeutics, Medical Devices, and Diagnostics With a Focus on Pre-Clinical Technologies
A venture capital firm with offices in Western Europe manages multiple life sciences investment funds focused on therapeutics, diagnostics, and medical devices. The firm specializes in early-stage healthcare investments and typically commits approximately €5–12M per portfolio company over multiple financing rounds. The firm primarily invests in European companies and is recognized for its hands-on investment approach and close collaboration with leading academic and clinical research institutions.
The firm invests across therapeutics, diagnostics, and medical devices, with a primary focus on therapeutics. The firm is modality- and indication-agnostic, evaluating innovative technologies that are approximately 12 months or less from entering the clinic, as well as programs in Phase I and Phase II clinical development. In addition to traditional venture investing, the firm operates as a company builder, collaborating with academic institutions and industrial partners to identify promising scientific discoveries and establish new biotechnology companies.
From a company and management team perspective, the firm seeks companies with differentiated science and clear value-creation pathways that can achieve strategic exit opportunities within approximately three to five years, often through partnerships or acquisitions by pharmaceutical companies. The firm works closely with founders, academic innovators, and industry partners to accelerate company formation, development, and commercialization.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Hot Investor Mandate: Investment Firm and Venture Builder Seeks Innovative Therapeutics Addressing Unmet Medical Need Backed by Strong Data
The firm is a therapeutics-focused venture builder and investment firm that partners with founders to discover, develop, and advance innovative medicines. The firm supports company creation through direct investments, focused spinouts, and de novo company formation. Combining venture investing with extensive drug discovery and development capabilities, the firm provides hands-on scientific, operational, and strategic support through a large multidisciplinary team of drug discovery experts, development professionals, and company builders. The firm invests through dedicated early- and clinical-stage funds, supporting programs from concept through key preclinical and clinical value-inflection milestones.
The firm invests exclusively in therapeutics and is agnostic across modalities and disease areas. The firm supports both single-asset and platform companies and is willing to invest across a broad spectrum of maturity, ranging from well-defined scientific concepts to companies with substantial preclinical proof-of-concept or early clinical data. The firm focuses on advancing programs through major development milestones, including preclinical validation, development candidate selection, and clinical demonstration of therapeutic activity.
From a company and management team perspective, the firm does not impose specific requirements regarding leadership composition. Instead, the firm works as a highly collaborative partner, providing scientific, operational, and strategic guidance to help founders optimize development plans, generate high-quality data, and maximize long-term value creation.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 